Skip to content
TriangleGet started
← Study library

NCT00094965 · CITED IN SOURCE DOCUMENTS

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2009-03-30

This trial is a phase II study in patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild, moderate and several renal dysfunction) based on their baseline measured creatinine clearance then treated with FOLFOX4. Standard bone marrow and liver function inclusion and exclusion criteria must be met prior to study treatment. FOLFOX4 in the study is given every 2 weeks (1 cycle = 2 weeks) for up to 12 cycles unless there are treatment delays to allow for recovery from toxic effects. Dose modifications are included for protocol specified toxicities. After 12 treatment cycles on study, patients who are having a beneficial disease response may continue to have oxaliplatin supplied off study to continue the treatment regimen until disease progression, prohibitive toxicity or death. Oxaliplatin pharmacokinetic studies (plasma and urine) are planned during cycles 1 and 2 on each patient. Creatinine clearance will be assessed every 2 cycles and disease status will be assessed every 3 cycles of treatment during the study.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed locally advanced or metastatic gastrointestinal (GI) malignancy; * Patients may have measurable or non-measurable disease; * Prior chemotherapy, radiation therapy, hormonal therapy and immunotherapy are allowed, with the exception that patients cannot have had prior treatment with oxaliplatin, cisplatin or other nephrotoxic anticancer agent; * Patients must have had no chemotherapy or radiotherapy within 4 weeks (28 days) prior to entering the study; * Age 18 or older; * Karnofsky performance status of 70% or greater for patients with normal or mildly abnormal renal function and 50% or greater for patients with moderately or severely abnormal renal function; * Life expectancy of at least 3 months; * Adequate bone marrow function (WBC \> or = 3000 cells/mm3, ANC \> or = 1500 cells/mm3, platelets \> or = 100,000 cells/mm3); * Adequate liver function (total bilirubin \< or =1.5 times the institutional upper limit of normal (IULN), AST (SGOT)/ALT (SGPT) \< or = 2 times the IULN, unless liver metastases are present and documented at baseline by CT or MRI scan (\< or = 5 times IULN in that case), alkaline phosphatase \< or = 2 times the IULN, unless liver metastases are present and documented at baseline by CT or MRI scan (\< or = 5 times IULN in that case)); * Patients may have a Grade 1 neurotoxicity at study entry. Absence of deep tendon reflexes as a sole neurological abnormality does not render the patient ineligible; * If female, not pregnant or lactating at inclusion. Documentation of a negative serum HCG pregnancy test for women of child bearing potential is required at inclusion; * Women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 6 months after discontinuation of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients with active hydronephrosis (patients with a functioning ureteral stent are allowed on study); * Patients who have had chemotherapy or radiotherapy within 4 weeks (28 days) prior to entering the study; * Patients who have had a major surgery within 4 weeks (28 days) prior to entering the study; * Patients who had prior therapy with oxaliplatin, cisplatin or other nephrotoxic anticancer agent; * History of allergy to platinum compounds; * Patients undergoing therapy with other investigational agents. Patients who received any investigational drug must have discontinued the investigational drug 30 days or more before beginning treatment on this study; * Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency; * Patients who have had a history of cardiac toxicities while on 5FU/LV therapy or myocardial infarction \< or = 6 months prior to study entry; * Patients with known brain metastases because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other toxicities; * Patients with interstitial pneumonia or extensive and symptomatic fibrosis of the lungs; * Patients with uncontrolled intercurrent illness (high blood pressure, unstable angina pectoris, symptomatic congestive heart failure (NYHA III or IV), severe cardiac arrhythmia, uncontrolled diabetes or active infection); * Pregnant or lactating women.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. intervention Names
    1. Drug: Oxaliplatin (SR96669)
    label
    1
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. 1
    description
    oxaliplatin in combination with FOLFOX4
    name
    Oxaliplatin (SR96669)
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
43
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Adverse events.
    time Frame
    12 Cycles
secondary Outcomes
  1. measure
    Pharmacokinetics.
    time Frame
    2 Cycles
  2. measure
    Tumor evaluations for response or progressive disease.
    time Frame
    12 Cycles
Full study description
brief Summary
This trial is a phase II study in patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild, moderate and several renal dysfunction) based on their baseline measured creatinine clearance then treated with FOLFOX4. Standard bone marrow and liver function inclusion and exclusion criteria must be met prior to study treatment. FOLFOX4 in the study is given every 2 weeks (1 cycle = 2 weeks) for up to 12 cycles unless there are treatment delays to allow for recovery from toxic effects. Dose modifications are included for protocol specified toxicities. After 12 treatment cycles on study, patients who are having a beneficial disease response may continue to have oxaliplatin supplied off study to continue the treatment regimen until disease progression, prohibitive toxicity or death. Oxaliplatin pharmacokinetic studies (plasma and urine) are planned during cycles 1 and 2 on each patient. Creatinine clearance will be assessed every 2 cycles and disease status will be assessed every 3 cycles of treatment during the study.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-4980095447e77ea7827f
      requested nct id
      NCT00094965
      primary nct id
      NCT00094965
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      payload sha256
      6ed6329d1d5117481f1a20688f5eb048cb0d0cfaecd479c62db16996322d6302
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-4980095447e77ea7827f
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00094965
      occurrences
      1. context exact
        l between the treatment arms in both studies.</li></ul></div></li><li>The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (<a href="/clinicaltrials/NCT00094965">BICC-C</a> [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer: FOL
        end
        256818
        exact text
        NCT00094965
        start
        256807
      2. context exact
        rms in both studies.</li></ul></div></li><li>The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (<a href="/clinicaltrials/NCT00094965">BICC-C</a> [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer: FOLFIRI, irinotecan plus bol
        end
        256843
        exact text
        NCT00094965
        start
        256832
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.943216+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
      source title
      Rectal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025
    2. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-df93b2fee659d327ca17
      requested nct id
      NCT00094965
      primary nct id
      NCT00094965
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
      payload sha256
      7612da45765e609a3fa9fcf85d6111421575701135044bdba1b6a66abc793f58
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-df93b2fee659d327ca17
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00094965
      occurrences
      1. context exact
        l between the treatment arms in both studies.</li></ul></div></li><li>The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (<a href="/clinicaltrials/NCT00094965">BICC-C</a> [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer, incl
        end
        199959
        exact text
        NCT00094965
        start
        199948
      2. context exact
        rms in both studies.</li></ul></div></li><li>The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (<a href="/clinicaltrials/NCT00094965">BICC-C</a> [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer, including FOLFIRI, irinotecan
        end
        199984
        exact text
        NCT00094965
        start
        199973
      3. context exact
        abindex="-1">Evidence (bevacizumab):</p> <div class="pdq-content-list"><ol id="_383"><li>After bevacizumab was approved, the <a href="/clinicaltrials/NCT00094965">BICC-C</a> trial was amended, and an additional 117 patients were randomly assigned to receive FOLFIRI/bevacizumab or mIFL/bevacizumab.<div class="pdq-content
        end
        204982
        exact text
        NCT00094965
        start
        204971
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/610f1b1dfbdfdb9c66.html
      source file sha256
      c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.940003+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      58f90914226eeac4b647c55350600c5f4db658e650463c199f43412e56552b42
      source title
      Colon Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025

    Preserved source evidence · Independent clinical review pending · Not medical advice